Cargando…
“Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM)
Obesity is largely undertreated, in part because of the stigma surrounding the disease and its treatment. The use of the term “weight loss drugs” to refer to medications for the treatment of obesity may contribute to this stigma, leading to the idea that anyone who wants to lose weight could use the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Endocrinologia e Metabologia
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665066/ https://www.ncbi.nlm.nih.gov/pubmed/37585688 http://dx.doi.org/10.20945/2359-4292-2023-0174 |
_version_ | 1785138748642557952 |
---|---|
author | Halpern, Bruno Mancini, Marcio C. van de Sande-Lee, Simone Miranda, Paulo Augusto Carvalho |
author_facet | Halpern, Bruno Mancini, Marcio C. van de Sande-Lee, Simone Miranda, Paulo Augusto Carvalho |
author_sort | Halpern, Bruno |
collection | PubMed |
description | Obesity is largely undertreated, in part because of the stigma surrounding the disease and its treatment. The use of the term “weight loss drugs” to refer to medications for the treatment of obesity may contribute to this stigma, leading to the idea that anyone who wants to lose weight could use them and that short-term use, only in the active weight loss phase would be enough. On the contrary, the use of terms such as “medications to treat obesity” or “anti-obesity medications” conveys the idea that the treatment is directed at the disease rather than the symptom. This joint statement by the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) intends to alert the press, healthcare professionals and scientific community about the importance of the appropriate use of language, with the aim of improving obesity care. |
format | Online Article Text |
id | pubmed-10665066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Sociedade Brasileira de Endocrinologia e Metabologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-106650662023-08-16 “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) Halpern, Bruno Mancini, Marcio C. van de Sande-Lee, Simone Miranda, Paulo Augusto Carvalho Arch Endocrinol Metab Consensus Obesity is largely undertreated, in part because of the stigma surrounding the disease and its treatment. The use of the term “weight loss drugs” to refer to medications for the treatment of obesity may contribute to this stigma, leading to the idea that anyone who wants to lose weight could use them and that short-term use, only in the active weight loss phase would be enough. On the contrary, the use of terms such as “medications to treat obesity” or “anti-obesity medications” conveys the idea that the treatment is directed at the disease rather than the symptom. This joint statement by the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) intends to alert the press, healthcare professionals and scientific community about the importance of the appropriate use of language, with the aim of improving obesity care. Sociedade Brasileira de Endocrinologia e Metabologia 2023-08-16 /pmc/articles/PMC10665066/ /pubmed/37585688 http://dx.doi.org/10.20945/2359-4292-2023-0174 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Consensus Halpern, Bruno Mancini, Marcio C. van de Sande-Lee, Simone Miranda, Paulo Augusto Carvalho “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) |
title | “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) |
title_full | “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) |
title_fullStr | “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) |
title_full_unstemmed | “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) |
title_short | “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) |
title_sort | “anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the brazilian association for the study of obesity and metabolic syndrome (abeso) and the brazilian society of endocrinology and metabolism (sbem) |
topic | Consensus |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665066/ https://www.ncbi.nlm.nih.gov/pubmed/37585688 http://dx.doi.org/10.20945/2359-4292-2023-0174 |
work_keys_str_mv | AT halpernbruno antiobesitymedicationsormedicationstotreatobesityinsteadofweightlossdrugswhylanguagemattersanofficialstatementofthebrazilianassociationforthestudyofobesityandmetabolicsyndromeabesoandthebraziliansocietyofendocrinologyandmetabolismsbem AT mancinimarcioc antiobesitymedicationsormedicationstotreatobesityinsteadofweightlossdrugswhylanguagemattersanofficialstatementofthebrazilianassociationforthestudyofobesityandmetabolicsyndromeabesoandthebraziliansocietyofendocrinologyandmetabolismsbem AT vandesandeleesimone antiobesitymedicationsormedicationstotreatobesityinsteadofweightlossdrugswhylanguagemattersanofficialstatementofthebrazilianassociationforthestudyofobesityandmetabolicsyndromeabesoandthebraziliansocietyofendocrinologyandmetabolismsbem AT mirandapauloaugustocarvalho antiobesitymedicationsormedicationstotreatobesityinsteadofweightlossdrugswhylanguagemattersanofficialstatementofthebrazilianassociationforthestudyofobesityandmetabolicsyndromeabesoandthebraziliansocietyofendocrinologyandmetabolismsbem |